These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8493420)

  • 41. Data monitoring boards in the pharmaceutical industry.
    Herson J
    Stat Med; 1993 Mar; 12(5-6):555-61; discussion 563. PubMed ID: 8493431
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.
    Bristow MR; Sharma K; Assmann SF; Linas S; Gersh BJ; Grady C; Rice MM; Singh S; Boineau R; McKinlay SM; Greenberg BH
    Eur J Heart Fail; 2017 Apr; 19(4):457-465. PubMed ID: 27873428
    [TBL] [Abstract][Full Text] [Related]  

  • 43. On independent data monitoring committees in oncology clinical trials.
    Wittes J; Schactman M
    Chin Clin Oncol; 2014 Sep; 3(3):40. PubMed ID: 25841466
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The agonising negative trend in monitoring of clinical trials.
    DeMets DL; Pocock SJ; Julian DG
    Lancet; 1999 Dec; 354(9194):1983-8. PubMed ID: 10622312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Practical issues in data monitoring of clinical trials: summary of responses to a questionnaire at NIH.
    Geller NL; Stylianou M
    Stat Med; 1993 Mar; 12(5-6):543-51; discussion 553. PubMed ID: 8493430
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical trial monitoring: hit or miss?
    Cohen J
    Science; 1994 Jun; 264(5165):1534-7. PubMed ID: 8202707
    [No Abstract]   [Full Text] [Related]  

  • 47. Data Safety and Monitoring Boards Should Be Required for Both Early- and Late-Phase Clinical Trials.
    Van Norman GA
    JACC Basic Transl Sci; 2021 Nov; 6(11):887-896. PubMed ID: 34869954
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maintaining data integrity in randomized clinical trials.
    Moody LE; McMillan S
    Nurs Res; 2002; 51(2):129-33. PubMed ID: 11984384
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Data monitoring committees and interim monitoring guidelines.
    Freidlin B; Korn EL; George SL
    Control Clin Trials; 1999 Oct; 20(5):395-407. PubMed ID: 10503800
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Site visit monitoring program of the clinical cooperative groups: results of the first 3 years.
    Mauer JK; Hoth DF; Macfarlane DK; Hammershaimb LD; Wittes RE
    Cancer Treat Rep; 1985 Oct; 69(10):1177-87. PubMed ID: 4042096
    [No Abstract]   [Full Text] [Related]  

  • 52. The conscientious judgement of a DSMB--statistical stopping rules re-examined.
    Hedenmalm K; Melander H; Alvan G
    Eur J Clin Pharmacol; 2008 Jan; 64(1):69-72. PubMed ID: 18000658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Designing a data and safety monitoring plan.
    Slimmer L; Andersen B
    West J Nurs Res; 2004 Nov; 26(7):797-803. PubMed ID: 15466615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A survey of monitoring practices in cancer clinical trials.
    George SL
    Stat Med; 1993 Mar; 12(5-6):435-50. PubMed ID: 8493422
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of data and safety monitoring in acute trauma resuscitation research.
    Champion HR; Fingerhut A; Escobar MA; Weiskopf RB
    J Am Coll Surg; 2007 Jan; 204(1):73-83. PubMed ID: 17189115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methodologic issues in terminating enrollment of a subgroup of patients in a multicenter randomized trial.
    Lee SM; Wise R; Sternberg AL; Tonascia J; Piantadosi S;
    Clin Trials; 2004; 1(3):326-38. PubMed ID: 16279258
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial.
    Gilpin AM; Holbrook JT; Jabs DA; Meinert CL;
    Control Clin Trials; 2003 Feb; 24(1):92-8. PubMed ID: 12559647
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design and analysis of group-randomized trials in cancer: A review of current practices.
    Murray DM; Pals SL; George SM; Kuzmichev A; Lai GY; Lee JA; Myles RL; Nelson SM
    Prev Med; 2018 Jun; 111():241-247. PubMed ID: 29551717
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Data and safety monitoring in social behavioral intervention trials: the REACH II experience.
    Czaja SJ; Schulz R; Belle SH; Burgio LD; Armstrong N; Gitlin LN; Coon DW; Martindale-Adams J; Klinger J; Stahl SM
    Clin Trials; 2006; 3(2):107-18. PubMed ID: 16773953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.